Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Nicotinic Receptors in Schizophrenia
NCT05462340Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]ASEM and [18F]AZAN in schizophrenia (4 arms), sponsored by Washington University School of Medicine. Primary endpoints: Receptor binding of [18F] ASEM-PET to nicotinic brain receptors (α7-nAChRs), Receptor binding of [18F]AZAN to α4β2 nicotinic acetylcholine receptors (α4β2-nAChR) and 7 more. Started Aug 2022; status: terminated.
02
Drugs
[18F]ASEM[18F]AZAN
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05462340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462340.